Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: A subanalysis of the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial

Shinya Goto, Jun Zhu, Lisheng Liu, Byung Hee Oh, Daniel M. Wojdyla, Philip Aylward, M. Cecilia Bahit, Bernard J. Gersh, Michael Hanna, John Horowitz, Renato D. Lopes, Lars Wallentin, Denis Xavier, John H. Alexander

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Background The perceived risk of serious bleeding is an obstacle to the use of oral anticoagulation in East Asia. The efficacy and safety of apixaban in East Asian patients with atrial fibrillation are unknown. Methods ARISTOTLE included 18,201 patients with nonvalvular atrial fibrillation randomized to apixaban 5 mg twice daily or warfarin. The efficacy and safety of apixaban and warfarin among patients recruited from East Asia (n = 1,993) were compared with those recruited from outside East Asia (n = 16,208). Results Compared with warfarin, apixaban resulted in a consistent reduction in stroke or systemic embolism in East Asian (hazard ratio [HR] 0.74, 95% CI 0.50-1.10) and non-East Asian (HR 0.81, 95% CI 0.66-0.99) patients (interaction P =.70). Consistent benefits of apixaban over warfarin were also seen for major bleeding in East Asian (HR 0.53, 95% CI 0.35-0.80) and non-East Asian (HR 0.72, 95% CI 0.62-0.83) patients (interaction P =.17). There was a greater reduction in major or clinically relevant nonmajor bleeding with apixaban compared with warfarin in East Asian (HR 0.49, 95% CI 0.35-0.67) than in non-East Asian (HR 0.71, 95% CI 0.63-0.79) patients (interaction P =.03). Numerically higher rates of intracranial bleeding were seen in East Asian patients with warfarin but not with apixaban. Conclusions Apixaban resulted in similar reductions in stroke or systemic embolism and major bleeding and greater reductions in major or clinically relevant nonmajor bleeding in patients from East Asia. Warfarin is associated with more intracranial bleeding, particularly in patients from East Asia.

LanguageEnglish
Pages303-309
Number of pages7
JournalAmerican Heart Journal
Volume168
Issue number3
DOIs
Publication statusPublished - 1 Jan 2014

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Goto, Shinya ; Zhu, Jun ; Liu, Lisheng ; Oh, Byung Hee ; Wojdyla, Daniel M. ; Aylward, Philip ; Bahit, M. Cecilia ; Gersh, Bernard J. ; Hanna, Michael ; Horowitz, John ; Lopes, Renato D. ; Wallentin, Lars ; Xavier, Denis ; Alexander, John H. / Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia : A subanalysis of the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. In: American Heart Journal. 2014 ; Vol. 168, No. 3. pp. 303-309.
@article{75abc9493be8414ab640a15fa7c2bce5,
title = "Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: A subanalysis of the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial",
abstract = "Background The perceived risk of serious bleeding is an obstacle to the use of oral anticoagulation in East Asia. The efficacy and safety of apixaban in East Asian patients with atrial fibrillation are unknown. Methods ARISTOTLE included 18,201 patients with nonvalvular atrial fibrillation randomized to apixaban 5 mg twice daily or warfarin. The efficacy and safety of apixaban and warfarin among patients recruited from East Asia (n = 1,993) were compared with those recruited from outside East Asia (n = 16,208). Results Compared with warfarin, apixaban resulted in a consistent reduction in stroke or systemic embolism in East Asian (hazard ratio [HR] 0.74, 95{\%} CI 0.50-1.10) and non-East Asian (HR 0.81, 95{\%} CI 0.66-0.99) patients (interaction P =.70). Consistent benefits of apixaban over warfarin were also seen for major bleeding in East Asian (HR 0.53, 95{\%} CI 0.35-0.80) and non-East Asian (HR 0.72, 95{\%} CI 0.62-0.83) patients (interaction P =.17). There was a greater reduction in major or clinically relevant nonmajor bleeding with apixaban compared with warfarin in East Asian (HR 0.49, 95{\%} CI 0.35-0.67) than in non-East Asian (HR 0.71, 95{\%} CI 0.63-0.79) patients (interaction P =.03). Numerically higher rates of intracranial bleeding were seen in East Asian patients with warfarin but not with apixaban. Conclusions Apixaban resulted in similar reductions in stroke or systemic embolism and major bleeding and greater reductions in major or clinically relevant nonmajor bleeding in patients from East Asia. Warfarin is associated with more intracranial bleeding, particularly in patients from East Asia.",
author = "Shinya Goto and Jun Zhu and Lisheng Liu and Oh, {Byung Hee} and Wojdyla, {Daniel M.} and Philip Aylward and Bahit, {M. Cecilia} and Gersh, {Bernard J.} and Michael Hanna and John Horowitz and Lopes, {Renato D.} and Lars Wallentin and Denis Xavier and Alexander, {John H.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.ahj.2014.06.005",
language = "English",
volume = "168",
pages = "303--309",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "3",

}

Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia : A subanalysis of the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. / Goto, Shinya; Zhu, Jun; Liu, Lisheng; Oh, Byung Hee; Wojdyla, Daniel M.; Aylward, Philip; Bahit, M. Cecilia; Gersh, Bernard J.; Hanna, Michael; Horowitz, John; Lopes, Renato D.; Wallentin, Lars; Xavier, Denis; Alexander, John H.

In: American Heart Journal, Vol. 168, No. 3, 01.01.2014, p. 303-309.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia

T2 - American Heart Journal

AU - Goto, Shinya

AU - Zhu, Jun

AU - Liu, Lisheng

AU - Oh, Byung Hee

AU - Wojdyla, Daniel M.

AU - Aylward, Philip

AU - Bahit, M. Cecilia

AU - Gersh, Bernard J.

AU - Hanna, Michael

AU - Horowitz, John

AU - Lopes, Renato D.

AU - Wallentin, Lars

AU - Xavier, Denis

AU - Alexander, John H.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background The perceived risk of serious bleeding is an obstacle to the use of oral anticoagulation in East Asia. The efficacy and safety of apixaban in East Asian patients with atrial fibrillation are unknown. Methods ARISTOTLE included 18,201 patients with nonvalvular atrial fibrillation randomized to apixaban 5 mg twice daily or warfarin. The efficacy and safety of apixaban and warfarin among patients recruited from East Asia (n = 1,993) were compared with those recruited from outside East Asia (n = 16,208). Results Compared with warfarin, apixaban resulted in a consistent reduction in stroke or systemic embolism in East Asian (hazard ratio [HR] 0.74, 95% CI 0.50-1.10) and non-East Asian (HR 0.81, 95% CI 0.66-0.99) patients (interaction P =.70). Consistent benefits of apixaban over warfarin were also seen for major bleeding in East Asian (HR 0.53, 95% CI 0.35-0.80) and non-East Asian (HR 0.72, 95% CI 0.62-0.83) patients (interaction P =.17). There was a greater reduction in major or clinically relevant nonmajor bleeding with apixaban compared with warfarin in East Asian (HR 0.49, 95% CI 0.35-0.67) than in non-East Asian (HR 0.71, 95% CI 0.63-0.79) patients (interaction P =.03). Numerically higher rates of intracranial bleeding were seen in East Asian patients with warfarin but not with apixaban. Conclusions Apixaban resulted in similar reductions in stroke or systemic embolism and major bleeding and greater reductions in major or clinically relevant nonmajor bleeding in patients from East Asia. Warfarin is associated with more intracranial bleeding, particularly in patients from East Asia.

AB - Background The perceived risk of serious bleeding is an obstacle to the use of oral anticoagulation in East Asia. The efficacy and safety of apixaban in East Asian patients with atrial fibrillation are unknown. Methods ARISTOTLE included 18,201 patients with nonvalvular atrial fibrillation randomized to apixaban 5 mg twice daily or warfarin. The efficacy and safety of apixaban and warfarin among patients recruited from East Asia (n = 1,993) were compared with those recruited from outside East Asia (n = 16,208). Results Compared with warfarin, apixaban resulted in a consistent reduction in stroke or systemic embolism in East Asian (hazard ratio [HR] 0.74, 95% CI 0.50-1.10) and non-East Asian (HR 0.81, 95% CI 0.66-0.99) patients (interaction P =.70). Consistent benefits of apixaban over warfarin were also seen for major bleeding in East Asian (HR 0.53, 95% CI 0.35-0.80) and non-East Asian (HR 0.72, 95% CI 0.62-0.83) patients (interaction P =.17). There was a greater reduction in major or clinically relevant nonmajor bleeding with apixaban compared with warfarin in East Asian (HR 0.49, 95% CI 0.35-0.67) than in non-East Asian (HR 0.71, 95% CI 0.63-0.79) patients (interaction P =.03). Numerically higher rates of intracranial bleeding were seen in East Asian patients with warfarin but not with apixaban. Conclusions Apixaban resulted in similar reductions in stroke or systemic embolism and major bleeding and greater reductions in major or clinically relevant nonmajor bleeding in patients from East Asia. Warfarin is associated with more intracranial bleeding, particularly in patients from East Asia.

UR - http://www.scopus.com/inward/record.url?scp=84908545649&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2014.06.005

DO - 10.1016/j.ahj.2014.06.005

M3 - Article

VL - 168

SP - 303

EP - 309

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 3

ER -